The DOI matches its Crossref record; 169 of the 169 references it cites were found in a registry or an index.
Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges
Abstract
The therapeutic armamentarium of acute myeloid leukemia (AML) has rapidly expanded in the past few years, driven largely by translational research into its genomic landscape and an improved understanding of mechanisms of resistance to conventional therapies. However, primary and secondary drug resistance remains a substantial problem for most patients. Research into the mechanisms of resistance to these new agents is informing the development of the next class of AML drugs and the design of combination regimens aimed at optimally exploiting therapeutic vulnerabilities, with the ultimate goal of eradicating all subclones of the disease and increasing cure rates in AML.Significance: AML is a heterogeneous disease, characterized by a broad spectrum of molecular alterations that influence clinical outcomes and also provide potential targets for drug development. This review discusses the current and emerging therapeutic landscape of AML, highlighting novel classes of drugs and how our expanding knowledge of mechanisms of resistance are informing future therapies and providing new opportunities for effective combination strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Döhner, H., Estey, E., Grimwade, D., Amadori, S., Appelbaum, F. R., Büchner, T., Dombret, H., Ebert, B. L., Fenaux, P., Larson, R. A., et al. (2017) · Blood · doi:10.1182/blood-2016-08-733196 · Cited by 5,775
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Genomic classification and prognosis in acute myeloid leukemia
Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516192 · Cited by 4,350 · cited 6×
“In a comprehensive analysis of 1,540 patients with AML that incorporated cytogenetic analysis with genomic profiling, 11 mutually exclusive subtypes of AML were identified (3).”
BackgroundInfluentialFigueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766
Chimeric antigen receptor T-cell therapy—assessment and management of toxicities
Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.148 · Cited by 2,438
Self-citationMidostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
Stone, R. M., Mandrekar, S. J., Sanford, B. L., Laumann, K., Geyer, S., Bloomfield, C. D., Thiede, C., Prior, T. W., Döhner, K., Marcucci, G., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614359 · Cited by 2,250
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Patel, J. P., Gönen, M., Figueroa, M. E., Fernandez, H., Sun, Z., Racevskis, J., Van Vlierberghe, P., Dolgalev, I., Thomas, S., Aminova, O., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112304 · Cited by 1,946
Grimwade, D., Hills, R. K., Moorman, A. V., Walker, H., Chatters, S., Goldstone, A. H., Wheatley, K., Harrison, C. J., Burnett, A. K., & on behalf of the National Cancer Research Institute Adult Leukaemia Working Group (2010) · Blood · doi:10.1182/blood-2009-11-254441 · Cited by 1,938
DiNardo, C. D., Pratz, K., Pullarkat, V., Jonas, B. A., Arellano, M., Becker, P. S., Frankfurt, O., Konopleva, M., Wei, A. H., Kantarjian, H. M., et al. (2019) · Blood · doi:10.1182/blood-2018-08-868752 · Cited by 1,825
Self-citationMajeti, R., Chao, M. P., Alizadeh, A. A., Pang, W. W., Jaiswal, S., Gibbs, K. D., van Rooijen, N., & Weissman, I. L. (2009) · Cell · doi:10.1016/j.cell.2009.05.045 · Cited by 1,752
Willingham, S. B., Volkmer, J.-P., Gentles, A. J., Sahoo, D., Dalerba, P., Mitra, S. S., Wang, J., Contreras-Trujillo, H., Martin, R., Cohen, J. D., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121623109 · Cited by 1,666
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
Lo-Coco, F., Avvisati, G., Vignetti, M., Thiede, C., Orlando, S. M., Iacobelli, S., Ferrara, F., Fazi, P., Cicconi, L., Di Bona, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300874 · Cited by 1,611
The roles of FLT3 in hematopoiesis and leukemia
Gilliland, D. G., & Griffin, J. D. (2002) · Blood · doi:10.1182/blood-2002-02-0492 · Cited by 1,558
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Stein, E. M., DiNardo, C. D., Pollyea, D. A., Fathi, A. T., Roboz, G. J., Altman, J. K., Stone, R. M., DeAngelo, D. J., Levine, R. L., Flinn, I. W., et al. (2017) · Blood · doi:10.1182/blood-2017-04-779405 · Cited by 1,516
Self-citationDurable Remissions with Ivosidenib in IDH1 -Mutated Relapsed or Refractory AML
DiNardo, C. D., Stein, E. M., de Botton, S., Roboz, G. J., Altman, J. K., Mims, A. S., Swords, R., Collins, R. H., Mannis, G. N., Pollyea, D. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716984 · Cited by 1,454
Self-citationLagadinou, E. D., Sach, A., Callahan, K., Rossi, R. M., Neering, S. J., Minhajuddin, M., Ashton, J. M., Pei, S., Grose, V., O’Dwyer, K. M., et al. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2012.12.013 · Cited by 1,399
Kantarjian, H. M., Thomas, X. G., Dmoszynska, A., Wierzbowska, A., Mazur, G., Mayer, J., Gau, J.-P., Chou, W.-C., Buckstein, R., Cermak, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.9429 · Cited by 1,169
Self-citationDombret, H., Seymour, J. F., Butrym, A., Wierzbowska, A., Selleslag, D., Jang, J. H., Kumar, R., Cavenagh, J., Schuh, A. C., Candoni, A., et al. (2015) · Blood · doi:10.1182/blood-2015-01-621664 · Cited by 1,165
Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity
van Galen, P., Hovestadt, V., Wadsworth II, M. H., Hughes, T. K., Griffin, G. K., Battaglia, S., Verga, J. A., Stephansky, J., Pastika, T. J., Lombardi Story, J., et al. (2019) · Cell · doi:10.1016/j.cell.2019.01.031 · Cited by 1,164
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
Advani, R., Flinn, I., Popplewell, L., Forero, A., Bartlett, N. L., Ghosh, N., Kline, J., Roschewski, M., LaCasce, A., Collins, G. P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1807315 · Cited by 1,126
Biological and therapeutic impact of intratumor heterogeneity in cancer evolution
McGranahan, N., & Swanton, C. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.12.001 · Cited by 1,077
Konopleva, M., Pollyea, D. A., Potluri, J., Chyla, B., Hogdal, L., Busman, T., McKeegan, E., Salem, A. H., Zhu, M., Ricker, J. L., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0313 · Cited by 1,064
Self-citationThe MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
Kotschy, A., Szlavik, Z., Murray, J., Davidson, J., Maragno, A. L., Le Toumelin-Braizat, G., Chanrion, M., Kelly, G. L., Gong, J.-N., Moujalled, D. M., et al. (2016) · Nature · doi:10.1038/nature19830 · Cited by 1,047
Castaigne, S., Pautas, C., Terré, C., Raffoux, E., Bordessoule, D., Bastie, J.-N., Legrand, O., Thomas, X., Turlure, P., Reman, O., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60485-1 · Cited by 1,015
High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia
Löwenberg, B., Ossenkoppele, G. J., van Putten, W., Schouten, H. C., Graux, C., Ferrant, A., Sonneveld, P., Maertens, J., Jongen-Lavrencic, M., von Lilienfeld-Toal, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901409 · Cited by 828
Issa, J.-P. J., Garcia-Manero, G., Giles, F. J., Mannari, R., Thomas, D., Faderl, S., Bayar, E., Lyons, J., Rosenfeld, C. S., Cortes, J., et al. (2004) · Blood · doi:10.1182/blood-2003-03-0687 · Cited by 809
Genetic variegation of clonal architecture and propagating cells in leukaemia
Anderson, K., Lutz, C., van Delft, F. W., Bateman, C. M., Guo, Y., Colman, S. M., Kempski, H., Moorman, A. V., Titley, I., Swansbury, J., et al. (2011) · Nature · doi:10.1038/nature09650 · Cited by 806
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
Welch, J. S., Petti, A. A., Miller, C. A., Fronick, C. C., O’Laughlin, M., Fulton, R. S., Wilson, R. K., Baty, J. D., Duncavage, E. J., Tandon, B., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1605949 · Cited by 796
Short, N. J., Rytting, M. E., & Cortes, J. E. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31041-9 · Cited by 781
Self-citationClonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia
Jan, M., Snyder, T. M., Corces-Zimmerman, M. R., Vyas, P., Weissman, I. L., Quake, S. R., & Majeti, R. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004315 · Cited by 721
Hills, R. K., Castaigne, S., Appelbaum, F. R., Delaunay, J., Petersdorf, S., Othus, M., Estey, E. H., Dombret, H., Chevret, S., Ifrah, N., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70281-5 · Cited by 721
Wei, A. H., Strickland, S. A., Hou, J.-Z., Fiedler, W., Lin, T. L., Walter, R. B., Enjeti, A., Tiong, I. S., Savona, M., Lee, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01600 · Cited by 692
Yang, H., Bueso-Ramos, C., DiNardo, C., Estecio, M. R., Davanlou, M., Geng, Q.-R., Fang, Z., Nguyen, M., Pierce, S., Wei, Y., et al. (2014) · Leukemia · doi:10.1038/leu.2013.355 · Cited by 688
Self-citationBerger, R., Rotem-Yehudar, R., Slama, G., Landes, S., Kneller, A., Leiba, M., Koren-Michowitz, M., Shimoni, A., & Nagler, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4079 · Cited by 680
Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation
Bhardwaj, G., Murdoch, B., Wu, D., Baker, D. P., Williams, K. P., Chadwick, K., Ling, L. E., Karanu, F. N., & Bhatia, M. (2001) · Nature Immunology · doi:10.1038/84282 · Cited by 677
Zhou, Q., Munger, M. E., Veenstra, R. G., Weigel, B. J., Hirashima, M., Munn, D. H., Murphy, W. J., Azuma, M., Anderson, A. C., Kuchroo, V. K., et al. (2011) · Blood · doi:10.1182/blood-2010-10-310425 · Cited by 675
The secret ally: immunostimulation by anticancer drugs
Galluzzi, L., Senovilla, L., Zitvogel, L., & Kroemer, G. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3626 · Cited by 670
Evolution of the cancer genome
Yates, L. R., & Campbell, P. J. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3317 · Cited by 640
Petersdorf, S. H., Kopecky, K. J., Slovak, M., Willman, C., Nevill, T., Brandwein, J., Larson, R. A., Erba, H. P., Stiff, P. J., Stuart, R. K., et al. (2013) · Blood · doi:10.1182/blood-2013-01-466706 · Cited by 638
Weisberg, E., Boulton, C., Kelly, L. M., Manley, P., Fabbro, D., Meyer, T., Gilliland, D. G., & Griffin, J. D. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00069-7 · Cited by 599
Hamann, P. R., Hinman, L. M., Hollander, I., Beyer, C. F., Lindh, D., Holcomb, R., Hallett, W., Tsou, H.-R., Upeslacis, J., Shochat, D., et al. (2002) · Bioconjugate Chemistry · doi:10.1021/bc010021y · Cited by 594
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
Davids, M. S., Kim, H. T., Bachireddy, P., Costello, C., Liguori, R., Savell, A., Lukez, A. P., Avigan, D., Chen, Y.-B., McSweeney, P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1601202 · Cited by 593
Graft-versus-leukemia effects of transplantation and donor lymphocytes
Kolb, H.-J. (2008) · Blood · doi:10.1182/blood-2008-03-077974 · Cited by 582
Diagnosing and exploiting cancer's addiction to blocks in apoptosis
Letai, A. G. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2297 · Cited by 580
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia
Chan, S. M., Thomas, D., Corces-Zimmerman, M. R., Xavy, S., Rastogi, S., Hong, W.-J., Zhao, F., Medeiros, B. C., Tyvoll, D. A., & Majeti, R. (2015) · Nature Medicine · doi:10.1038/nm.3788 · Cited by 577
Daver, N., Garcia-Manero, G., Basu, S., Boddu, P. C., Alfayez, M., Cortes, J. E., Konopleva, M., Ravandi-Kashani, F., Jabbour, E., Kadia, T., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0774 · Cited by 555
Self-citationGenomics of Acute Myeloid Leukemia Diagnosis and Pathways
Bullinger, L., Döhner, K., & Döhner, H. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.2208 · Cited by 541
Burnett, A. K., Russell, N. H., Hills, R. K., Bowen, D., Kell, J., Knapper, S., Morgan, Y. G., Lok, J., Grech, A., Jones, G., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00193-x · Cited by 534
MDM2 inhibitors for cancer therapy
Vassilev, L. T. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.11.002 · Cited by 532
Cortes, J. E., Heidel, F. H., Hellmann, A., Fiedler, W., Smith, B. D., Robak, T., Montesinos, P., Pollyea, D. A., DesJardins, P., Ottmann, O., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0312-9 · Cited by 496
Perl, A. E., Altman, J. K., Cortes, J., Smith, C., Litzow, M., Baer, M. R., Claxton, D., Erba, H. P., Gill, S., Goldberg, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30416-3 · Cited by 490
Targeting Alterations in the RAF–MEK Pathway
Yaeger, R., & Corcoran, R. B. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1321 · Cited by 465
McMahon, C. M., Ferng, T., Canaani, J., Wang, E. S., Morrissette, J. J. D., Eastburn, D. J., Pellegrino, M., Durruthy-Durruthy, R., Watt, C. D., Asthana, S., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1453 · Cited by 446
Caenepeel, S., Brown, S. P., Belmontes, B., Moody, G., Keegan, K. S., Chui, D., Whittington, D. A., Huang, X., Poppe, L., Cheng, A. C., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0387 · Cited by 432
Therapeutic strategies to target RAS-mutant cancers
Ryan, M. B., & Corcoran, R. B. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0105-0 · Cited by 420
PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model
Zhang, L., Gajewski, T. F., & Kline, J. (2009) · Blood · doi:10.1182/blood-2009-03-206672 · Cited by 411
MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy
Kojima, K., Konopleva, M., Samudio, I. J., Shikami, M., Cabreira-Hansen, M., McQueen, T., Ruvolo, V., Tsao, T., Zeng, Z., Vassilev, L. T., et al. (2005) · Blood · doi:10.1182/blood-2005-02-0553 · Cited by 407
Self-citationLehmann, S., Bykov, V. J. N., Ali, D., Andrén, O., Cherif, H., Tidefelt, U., Uggla, B., Yachnin, J., Juliusson, G., Moshfegh, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.7783 · Cited by 406 · cited 1×
“APR-246 is a novel agent that can restore transcriptional activity of unfolded wild-type or mutant p53, leading to induction of apoptosis in cancer cells with mutant p53 (78).”
BackgroundSchlenk, R. F., Kayser, S., Bullinger, L., Kobbe, G., Casper, J., Ringhoffer, M., Held, G., Brossart, P., Lübbert, M., Salih, H. R., et al. (2014) · Blood · doi:10.1182/blood-2014-05-578070 · Cited by 404
Araki, D., Wood, B. L., Othus, M., Radich, J. P., Halpern, A. B., Zhou, Y., Mielcarek, M., Estey, E. H., Appelbaum, F. R., & Walter, R. B. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.3826 · Cited by 400
Functional Heterogeneity of Genetically Defined Subclones in Acute Myeloid Leukemia
Klco, J. M., Spencer, D. H., Miller, C. A., Griffith, M., Lamprecht, T. L., O’Laughlin, M., Fronick, C., Magrini, V., Demeter, R. T., Fulton, R. S., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.031 · Cited by 395
Human Tumor Cells Killed by Anthracyclines Induce a Tumor-Specific Immune Response
Fucikova, J., Kralikova, P., Fialova, A., Brtnicky, T., Rob, L., Bartunkova, J., & Špíšek, R. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0950 · Cited by 392
Platzbecker, U., Avvisati, G., Cicconi, L., Thiede, C., Paoloni, F., Vignetti, M., Ferrara, F., Divona, M., Albano, F., Efficace, F., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.1982 · Cited by 389
Jacque, N., Ronchetti, A. M., Larrue, C., Meunier, G., Birsen, R., Willems, L., Saland, E., Decroocq, J., Maciel, T. T., Lambert, M., et al. (2015) · Blood · doi:10.1182/blood-2015-01-621870 · Cited by 387
Ramsey, H. E., Fischer, M. A., Lee, T., Gorska, A. E., Arrate, M. P., Fuller, L., Boyd, K. L., Strickland, S. A., Sensintaffar, J., Hogdal, L. J., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0140 · Cited by 379
Cairoli, R. (2006) · Blood · doi:10.1182/blood-2005-09-3640 · Cited by 375
Amadori, S., Suciu, S., Selleslag, D., Aversa, F., Gaidano, G., Musso, M., Annino, L., Venditti, A., Voso, M. T., Mazzone, C., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.0060 · Cited by 362
Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation
Nasr, R., Guillemin, M.-C., Ferhi, O., Soilihi, H., Peres, L., Berthier, C., Rousselot, P., Robledo-Sarmiento, M., Lallemand-Breitenbach, V., Gourmel, B., et al. (2008) · Nature Medicine · doi:10.1038/nm.1891 · Cited by 354
Stein, E. M., DiNardo, C. D., Fathi, A. T., Pollyea, D. A., Stone, R. M., Altman, J. K., Roboz, G. J., Patel, M. R., Collins, R., Flinn, I. W., et al. (2019) · Blood · doi:10.1182/blood-2018-08-869008 · Cited by 331
Self-citationWilliams, P., Basu, S., Garcia‐Manero, G., Hourigan, C. S., Oetjen, K. A., Cortes, J. E., Ravandi, F., Jabbour, E. J., Al‐Hamal, Z., Konopleva, M., et al. (2019) · Cancer · doi:10.1002/cncr.31896 · Cited by 330 · cited 2×
“Compared with healthy controls, patients with AML have increased T-regulatory cell infiltration and increased inhibitory coreceptor expression on CD8+ T cells, including PD-1, TIM3, and LAG3 (139).”
BackgroundSelf-citationPathways and mechanisms of venetoclax resistance
Bose, P., Gandhi, V., & Konopleva, M. (2017) · Leukemia & Lymphoma · doi:10.1080/10428194.2017.1283032 · Cited by 302
Self-citationKeilholz, U., Letsch, A., Busse, A., Asemissen, A. M., Bauer, S., Blau, I. W., Hofmann, W.-K., Uharek, L., Thiel, E., & Scheibenbogen, C. (2009) · Blood · doi:10.1182/blood-2009-02-202598 · Cited by 300
Pan, R., Ruvolo, V., Mu, H., Leverson, J. D., Nichols, G., Reed, J. C., Konopleva, M., & Andreeff, M. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.11.003 · Cited by 300
Self-citationTherapeutic targeting of acute myeloid leukemia stem cells
Pollyea, D. A., & Jordan, C. T. (2017) · Blood · doi:10.1182/blood-2016-10-696039 · Cited by 299
Zhou, Q., Munger, M. E., Highfill, S. L., Tolar, J., Weigel, B. J., Riddle, M., Sharpe, A. H., Vallera, D. A., Azuma, M., Levine, B. L., et al. (2010) · Blood · doi:10.1182/blood-2010-03-275446 · Cited by 287
Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations
Intlekofer, A. M., Shih, A. H., Wang, B., Nazir, A., Rustenburg, A. S., Albanese, S. K., Patel, M., Famulare, C., Correa, F. M., Takemoto, N., et al. (2018) · Nature · doi:10.1038/s41586-018-0251-7 · Cited by 281
Yoshimoto, G., Miyamoto, T., Jabbarzadeh-Tabrizi, S., Iino, T., Rocnik, J. L., Kikushige, Y., Mori, Y., Shima, T., Iwasaki, H., Takenaka, K., et al. (2009) · Blood · doi:10.1182/blood-2008-12-196055 · Cited by 272
Cortes, J., Perl, A. E., Döhner, H., Kantarjian, H., Martinelli, G., Kovacsovics, T., Rousselot, P., Steffen, B., Dombret, H., Estey, E., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30240-7 · Cited by 266
Kadia, T. M., Jain, P., Ravandi, F., Garcia‐Manero, G., Andreef, M., Takahashi, K., Borthakur, G., Jabbour, E., Konopleva, M., Daver, N. G., et al. (2016) · Cancer · doi:10.1002/cncr.30203 · Cited by 261
Self-citationCD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies
Testa, U., Pelosi, E., & Frankel, A. (2014) · Biomarker Research · doi:10.1186/2050-7771-2-4 · Cited by 255
Pollyea, D. A., Tallman, M. S., de Botton, S., Kantarjian, H. M., Collins, R., Stein, A. S., Frattini, M. G., Xu, Q., Tosolini, A., See, W. L., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0472-2 · Cited by 249
Self-citationBakker, A. B. H., van den Oudenrijn, S., Bakker, A. Q., Feller, N., van Meijer, M., Bia, J. A., Jongeneelen, M. A. C., Visser, T. J., Bijl, N., Geuijen, C. A. W., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1659 · Cited by 247
Mohi, M. G., Boulton, C., Gu, T.-L., Sternberg, D. W., Neuberg, D., Griffin, J. D., Gilliland, D. G., & Neel, B. G. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400063101 · Cited by 239
Kim, K.-T., Baird, K., Ahn, J.-Y., Meltzer, P., Lilly, M., Levis, M., & Small, D. (2005) · Blood · doi:10.1182/blood-2004-05-2006 · Cited by 234
Stringaris, K., Sekine, T., Khoder, A., Alsuliman, A., Razzaghi, B., Sargeant, R., Pavlu, J., Brisley, G., de Lavallade, H., Sarvaria, A., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.087536 · Cited by 231
Pellegrino, M., Sciambi, A., Treusch, S., Durruthy-Durruthy, R., Gokhale, K., Jacob, J., Chen, T. X., Geis, J. A., Oldham, W., Matthews, J., et al. (2018) · Genome Research · doi:10.1101/gr.232272.117 · Cited by 228
Harding, J. J., Lowery, M. A., Shih, A. H., Schvartzman, J. M., Hou, S., Famulare, C., Patel, M., Roshal, M., Do, R. K., Zehir, A., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0877 · Cited by 223
Targeting NEDD8-Activated Cullin-RING Ligases for the Treatment of Cancer
Soucy, T. A., Smith, P. G., & Rolfe, M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0343 · Cited by 222
Brandts, C. H., Sargin, B., Rode, M., Biermann, C., Lindtner, B., Schwäble, J., Buerger, H., Müller-Tidow, C., Choudhary, C., McMahon, M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0422 · Cited by 212
FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors
Smith, C. C., Lin, K., Stecula, A., Sali, A., & Shah, N. P. (2015) · Leukemia · doi:10.1038/leu.2015.165 · Cited by 202
Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib
Quek, L., David, M. D., Kennedy, A., Metzner, M., Amatangelo, M., Shih, A., Stoilova, B., Quivoron, C., Heiblig, M., Willekens, C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0115-6 · Cited by 200
Fathi, A. T., DiNardo, C. D., Kline, I., Kenvin, L., Gupta, I., Attar, E. C., Stein, E. M., de Botton, S., & for the AG221-C-001 Study Investigators (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.4695 · Cited by 195
Self-citationHeterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis
Smith, C. C., Paguirigan, A., Jeschke, G. R., Lin, K. C., Massi, E., Tarver, T., Chin, C.-S., Asthana, S., Olshen, A., Travers, K. J., et al. (2017) · Blood · doi:10.1182/blood-2016-04-711820 · Cited by 184
Stein, E. M., Walter, R. B., Erba, H. P., Fathi, A. T., Advani, A. S., Lancet, J. E., Ravandi, F., Kovacsovics, T., DeAngelo, D. J., Bixby, D., et al. (2018) · Blood · doi:10.1182/blood-2017-06-789800 · Cited by 184
Self-citationKovtun, Y., Jones, G. E., Adams, S., Harvey, L., Audette, C. A., Wilhelm, A., Bai, C., Rui, L., Laleau, R., Liu, F., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018017517 · Cited by 181
Tomita, A., Kiyoi, H., & Naoe, T. (2013) · International Journal of Hematology · doi:10.1007/s12185-013-1354-4 · Cited by 179
Prediction of Resistance to Small Molecule FLT3 Inhibitors
Cools, J., Mentens, N., Furet, P., Fabbro, D., Clark, J. J., Griffin, J. D., Marynen, P., & Gilliland, D. G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2148 · Cited by 178
Moujalled, D. M., Pomilio, G., Ghiurau, C., Ivey, A., Salmon, J., Rijal, S., Macraild, S., Zhang, L., Teh, T.-C., Tiong, I.-S., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0261-3 · Cited by 174
Secondary mutations as mediators of resistance to targeted therapy in leukemia
Daver, N. G., Cortes, J. E., Ravandi, F., Patel, K. P., Burger, J. A., Konopleva, M. Y., & Kantarjian, H. M. (2015) · Blood · doi:10.1182/blood-2014-10-605808 · Cited by 170
Self-citationSchnorfeil, F. M., Lichtenegger, F. S., Emmerig, K., Schlueter, M., Neitz, J. S., Draenert, R., Hiddemann, W., & Subklewe, M. S. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0189-2 · Cited by 165
FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
Traer, E., Martinez, J., Javidi-Sharifi, N., Agarwal, A., Dunlap, J., English, I., Kovacsovics, T., Tyner, J. W., Wong, M., & Druker, B. J. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3569 · Cited by 165
Park, I.-K., Mundy-Bosse, B., Whitman, S. P., Zhang, X., Warner, S. L., Bearss, D. J., Blum, W., Marcucci, G., & Caligiuri, M. A. (2015) · Leukemia · doi:10.1038/leu.2015.147 · Cited by 164
Rosenblatt, J., Stone, R. M., Uhl, L., Neuberg, D., Joyce, R., Levine, J. D., Arnason, J., McMasters, M., Luptakova, K., Jain, S., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aag1298 · Cited by 164
Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia
Maslak, P. G., Dao, T., Bernal, Y., Chanel, S. M., Zhang, R., Frattini, M., Rosenblat, T., Jurcic, J. G., Brentjens, R. J., Arcila, M. E., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2017014175 · Cited by 161
Lamba, J. K., Chauhan, L., Shin, M., Loken, M. R., Pollard, J. A., Wang, Y.-C., Ries, R. E., Aplenc, R., Hirsch, B. A., Raimondi, S. C., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.2513 · Cited by 159
Yamaura, T., Nakatani, T., Uda, K., Ogura, H., Shin, W., Kurokawa, N., Saito, K., Fujikawa, N., Date, T., Takasaki, M., et al. (2017) · Blood · doi:10.1182/blood-2017-05-786657 · Cited by 158
Uras, I. Z., Walter, G. J., Scheicher, R., Bellutti, F., Prchal‐Murphy, M., Tigan, A.-S., Valent, P., Heidel, F. H., Kubicek, S., Scholl, C., et al. (2016) · Blood · doi:10.1182/blood-2015-11-683581 · Cited by 149
Chyla, B., Daver, N. G., Doyle, K. J., McKeegan, E. M., Huang, X., Ruvolo, V. R., Wang, Z., Chen, K., Souers, A. J., Leverson, J. D., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25146 · Cited by 148
Self-citationYang, X., Sexauer, A. N., & Levis, M. J. (2013) · British Journal of Haematology · doi:10.1111/bjh.12599 · Cited by 140
Single-cell genotyping demonstrates complex clonal diversity in acute myeloid leukemia
Paguirigan, A. L., Smith, J., Meshinchi, S., Carroll, M., Maley, C., & Radich, J. P. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa0763 · Cited by 139
A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML
Breitenbuecher, F., Markova, B., Kasper, S., Carius, B., Stauder, T., Böhmer, F., Masson, K., Rönnstrand, L., Huber, C., Kindler, T., et al. (2009) · Blood · doi:10.1182/blood-2007-11-126664 · Cited by 128
Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML
Lindblad, O., Cordero, E., Puissant, A., Macaulay, L., Ramos, A. H., Kabir, N. N., Sun, J., Vallon‐Christersson, J., Haraldsson, K., Hemann, M. T., et al. (2016) · Oncogene · doi:10.1038/onc.2016.41 · Cited by 127
Clinical significance of B7-H1(PD-L1)expression in human acute leukemia
Chen, X., Liu, S., Wang, L., Zhang, W., Ji, Y., & Ma, X. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.5.5689 · Cited by 122
Jain, N., Curran, E. K., Iyengar, N. M., Díaz-Flores, E., Kunnavakkam, R., Popplewell, L. L., Kirschbaum, M. H., Karrison, T., Erba, H. P., Green, M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1311 · Cited by 122
Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia
Short, N. J., Kantarjian, H. M., Ravandi, F., & Daver, N. G. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620719827310 · Cited by 122
Self-citationShort, N. J., Kantarjian, H. M., Loghavi, S., Huang, X., Qiao, W., Borthakur, G., Kadia, T. M., Daver, N., Ohanian, M., Dinardo, C. D., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30182-0 · Cited by 120
Self-citationFerrando, A. A., & López-Otín, C. (2017) · Nature Medicine · doi:10.1038/nm.4410 · Cited by 120
Kohl, T. M., Hellinger, C., Ahmed, F., Buske, C., Hiddemann, W., Bohlander, S. K., & Spiekermann, K. (2007) · Leukemia · doi:10.1038/sj.leu.2404776 · Cited by 119
Han, L., Zhang, Q., Dail, M., Shi, C., Cavazos, A., Ruvolo, V. R., Zhao, Y., Kim, E. S., Rahmani, M., Mak, D. H. F., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.205534 · Cited by 116
Self-citationAnti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies
Pietsch, E. C., Dong, J., Cardoso, R., Zhang, X., Chin, D., Hawkins, R., Dinh, T., Zhou, M., Strake, B., Feng, P.-H., et al. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.7 · Cited by 115
Bagrintseva, K., Geisenhof, S., Kern, R., Eichenlaub, S., Reindl, C., Ellwart, J. W., Hiddemann, W., & Spiekermann, K. (2004) · Blood · doi:10.1182/blood-2004-06-2459 · Cited by 112
Kojima, K., McQueen, T. J., Chen, Y., Jacamo, R. O., Konopleva, M. Y., Shinojima, N., Shpall, E. J., Huang, X., & Andreeff, M. (2011) · Blood · doi:10.1182/blood-2011-02-334136 · Cited by 109
Self-citationAdam, M., Pogačić, V., Bendit, M., Chappuis, R., Nawijn, M. C., Duyster, J., Fox, C. J., Thompson, C. B., Cools, J., & Schwaller, J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2309 · Cited by 109
Lehmann, C. H. K., Friess, T., Birzele, F., Kiialainen, A., & Dangl, M. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0280-3 · Cited by 108
Paschka, P., Schlenk, R. F., Weber, D., Benner, A., Bullinger, L., Heuser, M., Gaidzik, V. I., Thol, F. R., Agrawal, M., Teleanu, V., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0129-6 · Cited by 107
MLN4924 induces Noxa upregulation in acute myelogenous leukemia and synergizes with Bcl-2 inhibitors
Knorr, K. L. B., Schneider, P., Meng, X. W., Dai, H., Smith, B. D., Hess, A. D., Karp, J. E., & Kaufmann, S. H. (2015) · Cell Death and Differentiation · doi:10.1038/cdd.2015.74 · Cited by 103
Green, A. S., Maciel, T. T., Yin, C., Mazed, F., Townsend, E. C., Pilorge, S., Lambert, M., Paubelle, É., Jacquel, A., Zylbersztejn, F., et al. (2015) · Science Advances · doi:10.1126/sciadv.1500221 · Cited by 102
Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia
Fan, M., Li, M., Gao, L., Geng, S., Wang, J., Wang, Y., Yan, Z., & Yu, L. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0519-7 · Cited by 100
Kadia, T. M., Cortes, J. E., Ravandi, F., Jabbour, E. J., Konopleva, M. Y., Benton, C. B., Burger, J. A., Sasaki, K., Borthakur, G. M., Dinardo, C. D., et al. (2018) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30132-7 · Cited by 98
Self-citationSingle cell analysis of clonal architecture in acute myeloid leukaemia
Potter, N. E., Miraki‐Moud, F., Ermini, L., Titley, I., Vijayaraghavan, G., Papaemmanuil, E., Campbell, P. J., Gribben, J. G., Taussig, D. C., & Greaves, M. F. (2018) · Leukemia · doi:10.1038/s41375-018-0319-2 · Cited by 98
Parmar, A., Marz, S., Rushton, S. N., Holzwarth, C., Lind, K., Käyser, S., Döhner, K., Peschel, C., Oostendorp, R. A. J., & Götze, K. S. S. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4136 · Cited by 96
Kornblau, S. M., Thall, P. F., Estrov, Z. E., Walterscheid, M., Patel, S., Theriault, A., Keating, M. J., Kantarjian, H. M., Estey, E., & Andreeff, M. (1999) · PubMed · Cited by 96
TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma
Jung, J., Lee, J. S., Dickson, M. A., Schwartz, G. K., Le Cesne, A., Varga, A., Bahleda, R., Wagner, A. J., Choy, E., de Jonge, M. J., et al. (2016) · Nature Communications · doi:10.1038/ncomms12609 · Cited by 95
Fathi, A. T., Erba, H. P., Lancet, J. E., Stein, E. M., Ravandi, F., Faderl, S. H., Walter, R. B., Advani, A. S., DeAngelo, D. J., Kovacsovics, T. J., et al. (2018) · Blood · doi:10.1182/blood-2018-03-841171 · Cited by 94
Self-citationConstitutively activated FLT3 phosphorylates BAD partially through Pim‐1
Kim, K., Levis, M. J., & Small, D. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06225.x · Cited by 93
Reis, B., Jukofsky, L., Chen, G., Martinelli, G., Zhong, H., So, W. V., Dickinson, M. J., Drummond, M., Assouline, S., Hashemyan, M., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.139717 · Cited by 91
Schimmer, A. D., Raza, A., Carter, T. H., Claxton, D. F., Erba, H. P., DeAngelo, D. J., Tallman, M. S., Goard, C. A., & Borthakur, G. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108694 · Cited by 86
Self-citationKoestner, W., Hapke, M., Herbst, J., Klein, C., Welte, K., Fruehauf, J., Flatley, A., Vignali, D. A. A., Hardtke‐Wolenski, M., Jaeckel, E., et al. (2010) · Blood · doi:10.1182/blood-2010-04-283119 · Cited by 85
Understanding the molecular pathogenesis of acute promyelocytic leukemia
Lo‐Coco, F., & Hasan, S. K. (2014) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2014.04.006 · Cited by 82
Natarajan, K., Xie, Y., Burcu, M., Linn, D. E., Qiu, Y., & Baer, M. R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074653 · Cited by 78
Graf, M., Reif, S., Hecht, K., Pelka‐Fleischer, R., Kroell, T., Pfister, K., & Schmetzer, H. M. (2004) · Annals of Hematology · doi:10.1007/s00277-004-0978-0 · Cited by 74
Swaminathan, M., Kantarjian, H. M., Daver, N. G., et al. (2017) · Blood · doi:10.1182/blood.v130.suppl_1.723.723 · Cited by 73
Self-citationGuo, Y. P., Strickland, S. A., Mohan, S. R., Li, S., Bosompem, A., Vickers, K. C., Zhao, S., Sheng, Q., & Kim, A. S. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1272680 · Cited by 71
Ragon, B. K., Odenike, O. M., Baer, M. R., Stock, W., Borthakur, G. M., Patel, K. P., Han, L., Chen, H., Ma, H., Joseph, L. J., et al. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.03.015 · Cited by 70
Self-citationWhiteway, A. J., Corbett, T., Anderson, R. W., Macdonald, I., & Prentice, H. G. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04085.x · Cited by 68
WT 1 vaccination in AML and MDS : A pilot trial with synthetic analog peptides
Brayer, J. B., Lancet, J. E., Powers, J. J., List, A. F., Balducci, L., Komrokji, R. S., & Pinilla-Ibarz, J. A. (2015) · American Journal of Hematology · doi:10.1002/ajh.24014 · Cited by 66
Sallman, D. A., Dezern, A. E., Steensma, D. P., Sweet, K. L., Cluzeau, T., Sekeres, M. A., Garcia‐Manero, G., Roboz, G. J., McLemore, A. F., McGraw, K. L., et al. (2018) · Blood · doi:10.1182/blood-2018-99-119990 · Cited by 66
Sallman, D. A., Donnellan, W. B., Asch, A. S., Lee, D. J., Malki, M. M. A., Marcucci, G., Pollyea, D. A., Kambhampati, S., Komrokji, R. S., Elk, J. V., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.7009 · Cited by 65
Zhang, W., Borthakur, G. M., Chen, G., Chen, Y., Mu, H., Ruvolo, V. R., Nomoto, K., Zhao, N., Konopleva, M. Y., & Andreeff, M. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1580 · Cited by 63
Self-citationPredictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition
Ishizawa, J., Nakamaru, K., Seki, T., Tazaki, K., Kojima, K., Chachad, D., Zhao, R., Heese, L. E., Ma, W., Ma, M. C. J., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-0949 · Cited by 60
Self-citationBuilding a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR
Perales, M.-A., Kebriaei, P., Kean, L. S., & Sadelain, M. (2018) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2017.10.017 · Cited by 59
Epigenetic Modulators and the New Immunotherapies
Dear, A. E. (2016) · New England Journal of Medicine · doi:10.1056/nejmcibr1514673 · Cited by 57
Advances in patient care through increasingly individualized therapy
Dinardo, C. D., & Perl, A. E. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0156-2 · Cited by 56
Self-citationRavandi, F., Bashey, A., Foran, J. M., et al. (2018) · Blood · doi:10.1182/blood-2018-99-119786 · Cited by 55
Self-citationShort, N. J., & Ravandi, F. (2019) · Haematologica · doi:10.3324/haematol.2018.208454 · Cited by 52
Self-citationKapoor, S., Natarajan, K., Baldwin, P. R., Doshi, K. A., Lapidus, R. G., Mathias, T. J., Scarpa, M., Trotta, R., Dávila, E., Kraus, M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1629 · Cited by 51
Fevery, S., Billiau, A., Sprangers, B., Rutgeerts, O., Lenaerts, C., Goebels, J., Landuyt, W., Kasran, A., Boon, L., Sagaert, X., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404720 · Cited by 49
Weisberg, E., Liu, Q., Zhang, X., Nelson, E. A., Sattler, M., Liu, F., Nicolais, M., Zhang, J., Mitsiades, C. S., Smith, R. W., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056473 · Cited by 43
Nivolumab (Nivo) maintenance (maint) in high-risk (HR) acute myeloid leukemia (AML) patients.
Kadia, T. M., Cortes, J. E., Ghorab, A., Ravandi, F., Jabbour, E. J., Daver, N. G., Alvarado, Y., Ohanian, M. N., Konopleva, M. Y., & Kantarjian, H. M. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.7014 · Cited by 43
Self-citationImpaired von Willebrand factor adhesion and platelet response in thrombospondin-2 knockout mice
Kristofik, N. J., Calabro, N. E., Tian, W., Meng, A., MacLauchlan, S., Wang, Y., Breuer, C. K., Tellides, G., Niklason, L. E., & Kyriakides, T. R. (2016) · Blood · doi:10.1182/blood-2016-03-702845 · Cited by 37
Rafiee, R., Chauhan, L., Alonzo, T. A., Wang, Y.-C., Elmasry, A., Loken, M. R., Pollard, J. A., Aplenc, R., Raimondi, S. C., Hirsch, B. A., et al. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0211-y · Cited by 36
Cortes, J. E., DeAngelo, D. J., Erba, H. P., Traer, E. A., Papadantonakis, N., Yi, C. A., Blum, W. G., Sloss, C. M., Culm-Merdek, K., Zweidler‐McKay, P. A., et al. (2018) · Blood · doi:10.1182/blood-2018-99-112891 · Cited by 34
Myeloid cell leukemia-1 dependence in acute myeloid leukemia: a novel approach to patient therapy
Kadia, T. M., Kantarjian, H. M., & Konopleva, M. Y. (2019) · Oncotarget · doi:10.18632/oncotarget.26579 · Cited by 28
Self-citationOnish, C., Mori, S., Hirade, T., Abe, M., Taketani, T., Suzumiya, J., Sugimoto, T., Yamaguchi, S., Kapur, R., & Fukuda, S. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.568287 · Cited by 25
Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia
Guerra, V. A., Jabbour, E. J., Ravandi, F., Kantarjian, H. M., & Short, N. J. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620719849496 · Cited by 23
Self-citationDaver, N. G., Garcia‐Manero, G., Basu, S., Cortes, J. E., Ravandi, F., Kadia, T. M., Konopleva, M. Y., Jabbour, E. J., Dinardo, C. D., Assi, R. E., et al. (2018) · Blood · doi:10.1182/blood-2018-99-120157 · Cited by 16
Self-citationActivity of venetoclax-based therapy in TP53-mutated acute myeloid leukemia.
Shoukier, M., Konopleva, M. Y., Dinardo, C. D., Ravandi, F., Andreeff, M., Garcia‐Manero, G., Jabbour, E. J., Daver, N. G., Borthakur, G. M., Pemmaraju, N., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.7034 · Cited by 10
Self-citation
Cited by
Acute myeloid leukemia: current progress and future directions
Kantarjian, H., Kadia, T., DiNardo, C., Daver, N., Borthakur, G., Jabbour, E., Garcia-Manero, G., Konopleva, M., & Ravandi, F. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00425-3 · Cited by 776
Self-citationEmerging agents and regimens for AML
Liu, H. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01062-w · Cited by 289
Sasaki, K., Ravandi, F., Kadia, T. M., DiNardo, C. D., Short, N. J., Borthakur, G., Jabbour, E., & Kantarjian, H. M. (2021) · Cancer · doi:10.1002/cncr.33458 · Cited by 276
Self-citationSong, Y., Zhang, L., Wang, Y., Han, M., Wang, Z., Wang, N., Shao, B., Li, R., Cao, K., Song, M., et al. (2023) · Advanced Materials · doi:10.1002/adma.202210895 · Cited by 54
Fischer, S., Weber, L. M., Stielow, B., Frech, M., Simon, C., Geller, M., Könnecke, J., Finkernagel, F., Forné, I., Nist, A., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae437 · Cited by 10
Metadata
- Authors
- Short, N. J., Konopleva, M., Kadia, T. M., Borthakur, G., Ravandi, F., DiNardo, C. D., & Daver, N.
- Venue
- Cancer Discovery
- Published
- 2020-04-01
- Volume
- 10
- Issue
- 4
- Pages
- 506-525
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W3005295900
- Cited by
- 368
- References
- 169
- FWCI
- 29.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.